Canaccord Genuity on Life Sciences/Biotechnology: BEST IDEAS FOR 2011: AMRN, DNDN, FOLD, NPSP, OREX, VRUS
AMRN Hot Sheet
Rating Summary:7 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Canaccord Genuity on Life Sciences/Biotechnology: BEST IDEAS FOR 2011: AMRN, DNDN, FOLD, NPSP, OREX, VRUS
Canaccord analyst says, "We believe that small and mid-cap biotech stock performance will continue to be driven by key catalysts: late-stage clinical data, FDA decisions, and sales growth. In addition to profiling each of our Best Ideas, we are providing quick updates on many of our coverage companies, including what we expect in 2011."
Amarin (Nasdaq: AMRN). AMR101 had positive data from its first pivotal trial in patients with very triglycerides.
Amicus (Nasdaq: FOLD). Amigal for Fabry disease is in a pivotal Phase 3 trial set to yield top-line data in H2/11.
Dendreon (Nasdaq: DNDN) is a Best Idea based on blockbuster sales potential for prostate cancer immunotherapy Provenge, fueled in the near term by continued manufacturing and commercial expansion as well as upcoming announcement of a European launch strategy.
NPS Pharmaceuticals (Nasdaq: NPSP) is a Best Idea based on 2011 expectations of highly compelling Phase 3 data read-out for previously-validated GATTEX in short bowel syndrome as well as hormone replacement drug NPSP558 in secondary hypoparathyroidism.
Orexigen (Nasdaq: OREX). Contrave for obesity recently received a positive FDA panel recommendation that we think paves the way for approval in 2011.
Pharmasset (Nasdaq: VRUS). Hepatitis C nuc polymerase inhibitors will be key components of future therapy, in our view. We expect key events in 2011, including: Phase 2b data and a Phase 3 start for Roche-partnered RG7128, Phase2b data for wholly owned PSI-7977, and data from Pharmasset’s proprietary all oral, two-nuc combination study of PSI-938 and PSI-7977.
Canaccord maintains a 'Buy' rating on all the above stocks
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Canaccord analyst says, "We believe that small and mid-cap biotech stock performance will continue to be driven by key catalysts: late-stage clinical data, FDA decisions, and sales growth. In addition to profiling each of our Best Ideas, we are providing quick updates on many of our coverage companies, including what we expect in 2011."
Amarin (Nasdaq: AMRN). AMR101 had positive data from its first pivotal trial in patients with very triglycerides.
Amicus (Nasdaq: FOLD). Amigal for Fabry disease is in a pivotal Phase 3 trial set to yield top-line data in H2/11.
Dendreon (Nasdaq: DNDN) is a Best Idea based on blockbuster sales potential for prostate cancer immunotherapy Provenge, fueled in the near term by continued manufacturing and commercial expansion as well as upcoming announcement of a European launch strategy.
NPS Pharmaceuticals (Nasdaq: NPSP) is a Best Idea based on 2011 expectations of highly compelling Phase 3 data read-out for previously-validated GATTEX in short bowel syndrome as well as hormone replacement drug NPSP558 in secondary hypoparathyroidism.
Orexigen (Nasdaq: OREX). Contrave for obesity recently received a positive FDA panel recommendation that we think paves the way for approval in 2011.
Pharmasset (Nasdaq: VRUS). Hepatitis C nuc polymerase inhibitors will be key components of future therapy, in our view. We expect key events in 2011, including: Phase 2b data and a Phase 3 start for Roche-partnered RG7128, Phase2b data for wholly owned PSI-7977, and data from Pharmasset’s proprietary all oral, two-nuc combination study of PSI-938 and PSI-7977.
Canaccord maintains a 'Buy' rating on all the above stocks
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UBS Maintains a 'Buy' on JPMorgan (JPM); Patient Investors Will Be Rewarded
- Oppenheimer Reiterates an 'Outperform' on MakeMyTrip (MMYT); Updating Estimates Ahead of March Qtr
- Compass Point Reiterates a 'Sell' on Post Properties (PPS); Adjusting Numbers
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
